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Complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) includes the risk of secondary
malignancies. This may be related to mechanisms including radiation and chemotherapy regimens, chronic graft-versus-
host disease, inflammation, and prolonged imunosuppression. Oral squamous cell carcinoma (OSCC) is a complication
associated with chronic graft-versus-host disease after allo-HSCT. Although human papillomavirus (HPV) is known to be
associated with OSCC, the role of HPV in development of OSCC in post-HSCT patients has not been studied. We identified
2 cases of OSCC in allo-HSCT recipients. Both biopsy specimens tested positive for p16INK4A, a surrogate marker for HPV.
We propose that the association of OSCC and HPV in patients after allo-HSCT may not be incidental. Clinical implications
of these cases may imply the need for a HPV screening, early intervention, and consideration of anti-HPV vaccination in
this population. The effectiveness of such interventions could be validated in a prospective clinical study. (Oral Surg Oral
Med Oral Pathol Oral Radiol 2014;118:e74-e78)With improved outcomes after allogeneic hematopoi-
etic stem cell transplantation (allo-HSCT), increasing
attention has been drawn to late complications in long-
term survivors. Among these, survivors of allo-HSCT
are at signiﬁcantly increased risk for developing sec-
ondary malignancies, with the incidence of secondary
solid tumors 2% to 6% at 10 years and 6% to 13% at 15
years.1-4 Squamous cell carcinoma (SCC) of the skin
and mouth is the most common secondary solid ma-
lignancy, accounting for one third of all secondary solid
tumors, with oral SCC (OSCC) representing 50% of
these cases.1,2,5 In one of the largest studies, Curtis
et al.1 analyzed 19,229 allo-HSCT patients from 235
centers and found that chronic graft-versus-host disease
(cGVHD) and male sex were strongly associated with
increased risk of OSCC.1 In a large multicenter Euro-
pean study, the actuarial risk of second malignances at
15 years was 11.5  2.3%.4 Furthermore, higher doses
of total body irradiation were associated with higher
incidence of solid tumors.1 Another larger study by
Rizzo et al. on 28,000 patients found that the risk of
SCC was 5 times higher in patients with cGVHD than
the general population.6 Bhatia et al. reported that 25%
late mortality in allo-HSCT survivors was attributed to
treatment-related causes, including 7% from secondary
malignancies.7 Patients with Fanconi’s anemia were
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survival.8,9
Possible mechanisms that have been proposed
include radiation mutagenesis, cGVHD-related inﬂam-
mation, prolonged immunosuppression for cGVHD,
immunologic dysfunction, and carcinogenic and cyto-
toxic effects of immunosuppressive therapy, or a
combination thereof.5,6,10 Post-HSCT OSCC has been
reported to occur in unusual sites such as the vermillion
border of the upper lip and the midline dorsum of the
tongue, buccal mucosa, or gingiva.11-13
The association of human papillomavirus (HPV) and
SCC of the oral cavity, female genital tract, and skin is
well established in the general population, and immu-
nosuppressed patients such as patients with human
immunodeﬁciency virus (HIV), patients who have un-
dergone cancer chemotherapy, and those who are solid
organ transplant recipients. HPV involvement in OSCC
was ﬁrst suggested by Syrjanen K et al.14 and
conﬁrmed by multiple studies thereafter.15-22 HPV has
been associated with OSCC diagnosed in the general
population in about one third of cases.19-22 In a pub-
lished meta-analysis of 5,046 head and neck SCC
cancer specimens from 60 studies, the overall HPV
prevalence was 25.9%; however, HPV prevalence was
signiﬁcantly higher in oropharyngeal SCC (35.6%).
HPV16 accounted for the majority of HPV-positiveStatement of Clinical Relevance
Screening for high risk human papilloma virus could
be considered in post allogeneic hematopoietic stem
cell transplantation patients with lesions suspicious
for oral carcinoma.
Fig. 1. (A) Clinical photograph from Case1 demonstrating a speckled red and white lesion of the buccal mucosa. (B) Photomi-
crograph from Case 1 demonstrating atypical bulbous proliferations and islands of neoplastic epithelium invading into the
connective tissue (hematoxylin-eosin, original magniﬁcation 50).
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genic HPVs were detected in HNSCC, in a recent
case-controlled study HPV16 DNA predominated,
occurring in 72% of 100 parafﬁn-embedded tumor
specimens of oropharyngeal cancer.17
The contribution of HPV to the higher incidence of
OSCC in allo-HSCT long-term survivors has not been
well deﬁned. In a small study, HPV was detected in 3
out of 5 cases of post-transplant OSCC.24 Three of
these patients had undergone allo-HSCT and had
cGVHD. In another study from Taiwan, half of the allo-
HSCT patients with secondary carcinoma had oral
squamous cell carcinoma; however, none of the tumors
had HPV infection according to immunohistochemistry
(IHC) staining.25 Special groups of patients who tend
to have high incidence of HNSCC after allo-HSCT are
the patients with Fanconi’s anemia and aplastic ane-
mia.8,26 These patients and patients with severe aplastic
anemia who undergo allo-HSCT were reported to have
a higher incidence of oral HPV, especially high-risk
HPV16, in comparison to healthy patients.27 Overall,
the reports about HPV involvement in OSCC after
HSCT are rather scant but may have a profound clinical
signiﬁcance.
An improved understanding of the clinical features
and potential factors associated with secondary OSCC,
as well as its course and treatment outcomes, may be
beneﬁcial in better understanding, predicting, and
managing this very serious late toxicity of allo-HSCT.
The objective of this report is to describe 2 cases of
OSSC after allo-HSCT that occurred in unusual sites
and in patients who were also positive for HPV.CASE REPORTS
Case 1
A 68-year-old man, a nonsmoker, was referred to the oral
medicine clinic for a nonhealing ulcer on the left buccal
mucosa. The patient’s medical history was signiﬁcant for in-
termediate grade large B-cell lymphoma that was treated 10
years ago by nonmyeloablative allo-HSCT, preceded by 200
cGy total body radiation in 1 fraction. The patient had a
history of skin and oral cGVHD. He had a relapse of hislymphoma isolated to the parotid and received rituximab for 2
years. He also has had monthly treatment with intravenous
immunoglobulin because of hypogammaglobulinemia and
recurrent infections but has maintained clinical remission of
his lymphoma since then.
Extra oral examination revealed a ﬁrm 1 cm lymph node on
the left inferior border of the mandible. The intraoral exami-
nation revealed a 1.5 cm  1 cm raised white ulcerated lesion
on the left buccal mucosa (Figure 1, A) with distinct borders
and speckled erythro-leukoplakia. The borders of the lesion
were ﬁrm and indurated. An incisional biopsy was performed
revealing large epithelial islands and atypical bulbous exten-
sions of neoplastic epithelium invading the underlying the
ﬁbrous connective tissue. The neoplastic epithelium displayed
signiﬁcant cytologic and morphologic alterations, including
increased nuclear/cytoplasmic ratios, nuclear hyper-
chromatism, individual cell keratinization, abnormal mitoses,
and formation of squamous eddies (Figure 1, B). A diagnosis
of superﬁcially invasive squamous cell carcinoma stage T1 M0
N1 was rendered. The patient underwent a wide local excision
and deep neck dissection with postoperative adjuvant radia-
tion therapy.Case 2
Case 2 was an 18-year-old male nonsmoker with acute
myeloid leukemia for which he had allo-HSCT from unre-
lated matched donor. The patient had a history of cGVHD on
the lower lip; he also had a fair complexion and a history of
sun exposure. Nine years after allo-HSCT, he developed a
crusty lesion on the vermillion border of the upper lip that
progressed into an indurated nodule (Figure 2, A). An inci-
sional biopsy of the lesion revealed widely invasive well-
differentiated squamous cell carcinoma with formation of
numerous islands and clusters of neoplastic cells. Extensive
keratin pearl formation along with nuclear and cellular
pleomorphism was noted throughout the specimen (Figure 2,
B). The malignancy was staged at T1 M0 N0. The patient’s
upper lip was subsequently treated with radiotherapy and the
cancer did not recur.Laboratory studies
Four mm thick sections were prepared from formalin-ﬁxed
parafﬁn-embedded tissue from cases 1 and 2 for IHC staining
with monoclonal antibodies against the tumor-suppressor
Fig. 2. (A) Clinical photograph from Case 2 depicting a nodular, ulcerated, and raised, rough, indurated lesion of the upper lip. (B)
Photomicrograph from Case 2 shows a widely invasive proliferation composed of small islands and clusters of malignant
epithelium with numerous keratin pearls and foci of individual cell keratinization (hematoxylin-eosin, original magniﬁcation 50).
Fig. 3. Photomicrograph of immunohistochemical stain for p16INK4A in the biopsy sample of Case 2 demonstrating strong positive
staining in majority of the invasive portions of the malignant process. (A) Bulbous extensions of neoplastic epithelium are noted.
(B) The neoplasm is more widespread and smaller islands with keratinization are noted throughout the stromal connective tissue
(original magniﬁcation 50).
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HPV infection.28,29 Sections were subsequently stained using
a Dako Autostainer Plus system (DAKO, DakoCytomation,
Glostrup, Denmark). Endogenous peroxidase activity was
quenched by incubating the slides in peroxidase blocking
reagent for 10 minutes. Incubation with mouse anti-human
p16INK4A monoclonal antibody (Santa Cruz Biotechnology,
Dallas, TX) (diluted 1:100) was performed for 30 minutes at
room temperature. Sites of binding were detected using 3,30-
diaminobenzidine as chromogen according to the manufac-
turer’s instructions. The sections were counterstained with
hematoxylin, dehydrated, cleared, and mounted. The sections
from both specimen were strongly reactive for p16INK4A
(Figure 3).
DISCUSSION
In this report, we describe 2 p16/HPV-positive OSCC
cases; both patients are males and 1 is young, 18 years
old. It has been known previously that there higher
prevalence of OSCC in males and that it can happen in
younger age in immunocompromised patients. This
report also brings up multiple important points that can
have clinical implications to the diagnosis, treatment,
and follow up of surviving patients with cGVHD after
allo-HSCT, including the following: Secondary OSCC
is a serious complication of these patients; HPV mayplay a role in the pathogenesis of such complication;
and testing for HPV by IHC for p16 is simple and
should be done on all patients with OSCC. These issues
may have wider application in patients who receive
intense chemotherapy and in patients undergoing solid
organ transplants.
Many questions remain, including whether the
detection of HPV represents a new infection of HPV or
a reactivation of a latent infection. Reactivation of latent
DNA viruses such as herpes simplex, varicella zoster,
human herpes virus 6, Epstein-Barr, cytomegalovirus,
and hepatitis B virus is known to happen after allo-
HSCT.30 Although HPV infection is common, studies
suggest approximately 90% of infections clear within 2
years.31 However, many patients in whom HPV has
been eliminated from the serum still have detectable
HPV DNA in tissues such as skin, in the oral cavity,
and in the female genital tract. Thus, after allo-HSCT,
renal transplantation, or intensive chemotherapy
dormant HPV may reactivate in these sites, leading to
benign and malignant tumors.31 A meta-analysis by
Grulich et al.32 indicated that HIV-infected patients and
solid organ transplant recipients had an increased inci-
dence of HPV-related cancers, including the genitalia
and oropharynx. HPV DNA was shown in the oral
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polymerase chain reaction) of 18% of renal transplant
versus 1% of control samples.33
Studies done on HPV vaccination of high-risk fe-
males have shed light on the immune response against
HPV. Natural immunity against HPV involves innate
and adaptive immune responses, predominated by a
robust, local cell-mediated immunity, which is associ-
ated with lesion regression and generation of serum
neutralizing antibodies.34,35 However, clearance of
HPV infection is diminished among immunocompro-
mised individuals, possibly leading to reactivation and
progression to malignant lesions.36,37 Furthermore,
there is evidence that seroreactivity against HPV can be
lost after allo-HSCT.38 This may imply that these pa-
tients may acquire the infection after HSCT. Thus the
need for HPV vaccination after allo-HSCT has been
discussed before.30,39 The timing and the population
target for such vaccination should be studied in a pro-
spective large study that may take many years to
complete.
In conclusion, we present 2 cases of posteallo-HSCT
OSCCs in patients who were positive for p16 HPV,
thus raising the issue of risk of HPV-related OSCC with
clinical implications for screening and early interven-
tion. A large cohort study is warranted to formulate
distinct clinical recommendation; however, patients at
risk, mainly long-term survivors with cGVHD, should
probably be screened for HPV using IHC or polymerase
chain reaction on oral brushings and if positive be
carefully and closely monitored for secondary OSCC
for early intervention and prevention.
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